According to the most recent analysis by Emergent Research, the size of the global assisted reproductive technology market is anticipated to reach USD 54.75 billion in 2028, growing at a consistent revenue CAGR of 9.7%.
The methods used to treat infertility are referred to as assisted reproductive technology, often known as an assisted reproductive treatment. Depending on the cause of infertility, these therapies span a wide range of techniques. In-vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo transfer (FET), and gamete intrafallopian transfer are methods that are often utilized to treat such disorders (GIFT). Assisted reproductive technologies don’t consist of a treatment that merely employs tablets; instead, they require procedures that handle both eggs and embryos.
Multiple factors, including the rising prevalence of infertility due to changing lifestyles, the general population’s rising stress levels, and the expansion of government initiatives to promote fertility services, are driving the demand for assisted reproductive technology. A further factor driving the growth of the fertility services market is the advent of cutting-edge assisted reproductive technologies like intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), gestational age at first transfer (GIFT), and frozen embryo transfer (FET).
The market for assisted reproductive technology is divided into segments based on the product, technology, end-user, and geographic location. The market is divided into the instrument, accessory, and disposable as well as reagent and media categories based on product. A further division of the instrument segment includes sperm separation systems, cryptosystems, incubators, imaging systems, ovum aspiration pumps, cabinets, micromanipulators, laser systems, and others. Cryopreservation media, semen processing media, ovum processing media, and embryo culture media make up the remainder of the reagent and media category.
Because of their known dependability and greater pregnancy success rate, frozen non-donor segment revenue is anticipated to expand at a much faster rate than the industry average throughout the projected period. When compared to cycles that employ fresh embryos and eggs, the method is less expensive. For both the patient and the reproductive endocrinologist, a frozen transfer is easier. Additionally, this process is less taxing on a woman’s body both mentally and physically.
Because artificial insemination does not involve the removal of eggs from the body, it is substantially less intrusive for women who are trying to get pregnant. This category accounted for a sizable portion of revenue in 2020. In this procedure, sperm is put directly into the uterus or cervix to induce conception. The procedure is also less expensive than IVF because it does not involve egg extraction or laboratory monitoring.
In 2020, the hospital category accounted for a remarkably sizable revenue share. The availability of assisted reproductive technology in hospitals is influenced by elements including well-equipped operating and surgery rooms, the presence of highly experienced medical personnel, and improved health coverage for healthcare services from various plans for individual and group insurance. A smaller revenue share could, however, be the outcome of a decreased adoption of the most recent and inventive upgrades.
Some major players in the market report include Origin, Cryolab Ltd., Bloom IVF Center, Ferring Pharmaceuticals, Cosmos Biomedical, Irvine Scientific, European Sperm Bank, Ovascience, Parallels, and Microm UK Ltd.
Emergen Research has segmented the global assisted reproductive technology market based on procedure, technology, end-user, and region:
Procedure Outlook (Revenue, USD Billion; 2018-2028)
- Fresh Donor
- Fresh Non-Donor
- Frozen Donor
- Frozen Non-Donor
- Egg/Embryo Banking
Technology Outlook (Revenue, USD Billion; 2018-2028)
- In-Vitro Fertilization (IVF)
- In-Vitro Fertilization (IVF) with Intracytoplasmic Sperm Injection (ICSI)
- In-Vitro Fertilization (IVF) without Intracytoplasmic Sperm Injection (ICSI)
- Artificial Insemination
- Frozen Embryo Transfer (FET)
- Others
End-Use Outlook (Revenue, USD Billion; 2018-2028)
- Hospitals
- Fertility Clinics
- Others
Regional Outlook (Revenue, USD Billion; 2018–2028)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- BENELUX
- Rest of Europe
- the Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- Rest Of MEA
To get leading market solutions, Visit the Link
